Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?
Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence? / Marchioni M.; Amparore D.; Marandino L.; Bertolo R.; Erdem S.; Ingels A.; Muselaers S.; Kara O.; Pavan N.; Roussel E.; Carbonara U.; Pecoraro A.; Diana P.; Pecoraro A.; Campi R.. - In: EUROPEAN UROLOGY OPEN SCIENCE. - ISSN 2666-1691. - ELETTRONICO. - 46:(2022), pp. 39-42. [10.1016/j.euros.2022.10.002]
Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?
Pecoraro A.;Campi R.
2022
Abstract
Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2666168322020407-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
1.06 MB
Formato
Adobe PDF
|
1.06 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
